Results 241 to 250 of about 44,321 (338)

Bone Formation and the Wnt Signaling Pathway. [PDF]

, 2016
Baron, R., Gori, F., Superti-Furga, A.
core   +1 more source

Inducible T‐Cell Co‐Stimulator (ICOS) and ICOS Ligand: Dealing With a Two‐Faced Cancer Immunoregulatory System

Cancer Medicine, Volume 15, Issue 1, January 2026.
ICOS (inducible T‐cell co‐stimulator) and ICOS ligand (ICOSL) are part of an important, complex pathway that can lead to both immune stimulation and suppression. Both ICOS agonists and antagonists are under development as oncology therapeutics and biomarker driven approaches will be important to ascertain which patients will derive the greatest benefit
Mina Nikanjam, Shumei Kato, Daisuke Nishizaki, Hirotaka Miyashita, Sarabjot Pabla, Mary K. Nesline, Heidi Ko, Jeffrey M. Conroy, Aung Naing, Razelle Kurzrock   +9 more
wiley   +1 more source

Current immunotherapeutic approaches for relapsed/refractory follicular lymphoma: bispecific antibodies and CAR T-Cell therapies. [PDF]

Blood Res
Park SY, Min GJ.
europepmc   +1 more source

Real‐World Outcomes of Polatuzumab Vedotin Plus R‐CHP Versus R‐CHOP‐Based Regimens in Japanese Patients With Untreated Diffuse Large B‐Cell Lymphoma

Cancer Medicine, Volume 15, Issue 1, January 2026.
PV‐R‐CHP showed improved progression‐free and overall survivals compared to R‐CHOP‐based regimens in newly diagnosed Japanese patients with DLBCL, particularly in those with non‐GCB subtype. These results were consistent in both the overall cohort and propensity score‐matched cohorts.
Masaaki Hotta, Atsushi Satake, Ayako Iwama, Tokiko Hoshiyama, Yukie Tsubokura, Hideaki Yoshimura, Shinya Fujita, Yumiko Kono, Tomoki Ito   +8 more
wiley   +1 more source

Emerging Risk of <i>Campylobacter</i> spp. Infection Associated With Anti-BCMA and Anti-GPRC5D Bispecific Antibodies. [PDF]

Open Forum Infect Dis
Bilbao I, Ansón M, Villar S, Pineda I, Gárriz L, Pina-Sánchez M, Tamariz-Amador LE, Rodríguez-Otero P, Yuste JR, Del Pozo JL.   +9 more
europepmc   +1 more source

Advancements in Targeted Radiopharmaceuticals: Innovations in Diagnosis and Therapy for Enhanced Cancer Management

ChemBioChem, Volume 27, Issue 1, January 2026.
Radiopharmaceuticals enable precise cancer diagnosis and targeted therapy by combining radioactive isotopes with carrier molecules. This review summarizes advances from 2014 to 2025, emphasizing probe design, click chemistry, novel targets, and nanodelivery systems.
Mohd Sayeed Shaikh, Rupesh R. Kurhade, Abrar A. M. Siddiqui, Shaikh Shahbaz A. Majeed, Thomas J. Webster, Mohammad Intakhab Alam, Abdul Wasy Zia, Md. Faiyazuddin   +7 more
wiley   +1 more source

Comparative infection risk in CAR T vs bispecific antibodies in B-cell lymphoma: a systematic review and meta-analysis. [PDF]

Blood Adv
van Besien H, Easwar N, Demetres M, Pasciolla M, Shore T, Leonard J, Barker J, Martin P, Yamshon S.   +8 more
europepmc   +1 more source

Massive Intra‐Abdominal Pseudotumor in a Patient With Hemophilia A Treated With Emicizumab: A Case Report

Clinical Case Reports, Volume 14, Issue 1, January 2026.
ABSTRACT Hemophilic pseudotumors, a rare complication of bleeding disorders, are more common in settings with limited access to clotting factor concentrates. Subcutaneous emicizumab, a relatively novel therapy for hemophilia A, was investigated for its ability to stabilize an inoperable pseudotumor in a patient with factor VIII deficiency in an under ...
C. J. Kilach, C. Njuguna, F. Njuguna, C. M. Wanjiku, K. F. Molitor, I. A. Janson, S. M. Mbunya, A. D. Shapiro, J. Sagar, A. Greist   +9 more
wiley   +1 more source

Data from IL-15/IL-15Rα-Fc-Fusion Protein XmAb24306 Potentiates Activity of CD3 Bispecific Antibodies through Enhancing T-Cell Expansion

Ji Li, Robyn Clark, Dionysos Slaga, Kendra N. Avery, Ke Liu, Suzanne Schubbert, Rajat Varma, Eugene Y. Chiang, Klára Tótpál, Matthew J. Bernett, Patrick G. Holder, Teemu T. Junttila   +11 more
openalex   +1 more source

General strategies for IgG‐like bispecific antibody purification [PDF]

Yifeng Li
openalex   +1 more source